Menu Back to Committee

Programme Steering Committee, Advisors and Topic Leaders

Introducing the DIA Europe 2018 Programme Steering Committee

REGULATORY SCIENCE CO-CHAIRS:

Pani Luca Luca Pani
Professor, Department of Psychiatry and Behavioral Sciences, University Of Miami School Of Medicine; Executive Director of Global Medical Innovation NeuroCog, USA

Michelle Rohrer
Global Head of PD Regulatory and Policy
F. Hoffmann-La Roche and Genentech, Switzerland

VALUE & ACCESS CO-CHAIRS:

Jens Grueger
Head of Global Pricing & Market Access
F. Hoffmann-La Roche, Switzerland

Ad Schuurman
A.R. (Ad) Schuurman
Head of International Department
National Health Care Institute (ZIN), Netherlands

TRANSLATIONAL MEDICINE & SCIENCE CHAIR:

Salah Dine Chibout
Salah-Dine Chibout
Global Head of Discovery & Investigative Safety (DIS)
Novartis Institutes, Switzerland

DOWNLOAD PROGRAMME

Program Committee

Salah-Dine Chibout • Global Head Discovery & Investigative Safety/Preclinical Safety Therapeutic Area
Novartis Pharma AG, Switzerland
Jens Grueger, PhD • Head Global Pricing & Market Access, Pharma Division
F. Hoffmann-La Roche, Switzerland
Luca Pani, MD • Former, AIFA; Professor, Department of Psychiatry and Behavioral Sciences
University of Miami, United States
Michelle Rohrer, PhD • Vice President, Global Head Regulatory Regions and Policy
Genentech, A Member of the Roche Group , United States
Vivianne Arencibia • Independent Consultant
Arencibia Quality and Compliance Associates, United States
Sabine Atzor, RPh •
F. Hoffmann La Roche Ltd, Switzerland
Ursula Busse, PhD, MBA • Head of Quality Intelligence, External Engagement
Novartis, Switzerland
João Duarte, MPharm • Associate Director, Regulatory Intelligence
Alexion Pharmaceuticals, France
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator
European Medicines Agency (EMA), United Kingdom
Cordula Landgraf, RPh • Head of Networking
Swissmedic, Switzerland
Francesco Pignatti, MD • Head of Oncology, Haematology, Diagnostics
European Medicines Agency (EMA), United Kingdom
Bettina Ryll • Chair ESMO Patient Advocates Working Group (PAWG)
Melanoma Patients, Sweden
Claudine Sapède, PharmD • Global HTA and Payment Policy Lead
F. Hoffmann-La Roche, Switzerland
Ad Schuurman, MBA, MSc • Head of the Business Contact Centre & International Affairs
National Health Care Institute (ZIN), Netherlands
Indranil Bagchi, PhD, MS • SVP and Head, Global Value and Access
Novartis Oncology, United States
Isabelle M de Zegher, DrMed, MD, MS, MSc • Vice President
PAREXEL Informatics, Belgium
Petra Doerr, PharmD, PhD, RPh • Deputy Executive Director
Swissmedic, Switzerland
Vicki Edwards, RPh • Vice President, Pharmacovigilance Excellence and QPPV
AbbVie, Inc., United Kingdom
Georgy Genov, MD • Head of Signal and Incident Management
European Medicines Agency, European Union, United Kingdom
Anthony Humphreys, MPharm • Head of Scientific Committees Regulatory Science Strategy
European Medicines Agency, European Union , United Kingdom
Merete Joergensen, MBA, MSc • Senior Trial Disclosure Director, Global Clinical Registry
Novo Nordisk A/S, Denmark
Jordi Llinares Garcia, MS • Head of Scientific and Regulatory Management
European Medicines Agency (EMA), United Kingdom
Manfred Maeder, PhD • Head of Device Development & Commercialization
Novartis, Switzerland
Thomas Metcalfe, MBA • Strategic Innovation Leader, Personalised Healthcare
F. Hoffmann-La Roche, Switzerland
Sharon Olmstead • Global Head, Development and Regulatory Policy
Novartis Pharmaceuticals Corporation, United States
Representative Invited • Merck KGaA, Germany
Thomas Senderovitz, DrMed, MD • Chair of HMA Management Group; Director General
Danish Medicines Agency, Denmark
Representative Invited • European Medicines Agency, European Union, United Kingdom